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Hypoxiaa b s t r a c t
Chronic hypoxia triggers pulmonary vascular remodeling, which is associated with de-differentia-
tion of pulmonary artery smooth muscle cells (PASMC). Here, we show that miR-20a expression is
up-regulated in response to hypoxia in both mouse and human PASMC. We also observed that
miR-20a represses the protein kinase, cGMP-dependent, type I (PRKG1) gene and we identiﬁed
two crucial miR-20a binding sites within the coding region of PRKG1. Functional studies showed
that miR-20a promotes the proliferation and migration of human PASMC, whereas it inhibits their
differentiation. In summary, we provided a possible mechanism by which hypoxia results in
decreased PRKG1 expression and in the phenotypic switching of PASMC.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction play roles in the abnormal proliferation and dedifferentiation ofPulmonary arterial hypertension (PAH) is a devastating,
life-threatening disease characterized by pulmonary vascular
remodeling, leading to a progressive increase in pulmonary vascu-
lar resistance, right ventricular failure and ultimately death [1].
Although the speciﬁc mechanisms responsible for the development
of PAH remain unclear, pulmonary vascular remodeling involving
abnormal proliferation, migration and dedifferentiation of pulmon-
ary arterial smooth muscle cells (PASMC) from a contractile,
differentiated phenotype to a synthetic, undifferentiated pheno-
type, is the key feature of PAH pathology [2]. A number of factorsPASMC among which hypoxia is an important stimulus.
Zhou et al. have demonstrated that the decreased expression
levels of smooth muscle cell contractile markers in hypoxia were
strongly related to a decrease in cGMP-dependent protein kinase
(PKG) expression and that this effect of hypoxia can be reversed
by PKG overexpression [3]. PKG is a serine/threonine-speciﬁc pro-
tein kinase in the nitric oxide/cGMP signaling pathway and plays
critical roles in regulating cardiovascular and neuronal functions
in addition to relaxing smooth muscle tone, preventing platelet
aggregation, and modulating cell growth [4]. Mammalian PKG
exists in two major forms: PKG-1, a soluble enzyme consisting of
a and b isoforms derived from alternative splicing from one gene,
that differ in the amino-terminal domain (through residues 89 and
104, respectively) and therefore contain identical catalytic
domains; and PKG-2, a membrane-associated form derived from
another gene [5,6]. Type 1 PKG, encoded by PRKG1 gene, is the only
PKG expressed in vascular smooth muscle cells [7]. Boerth et al. [7]
and Lincoln et al. [8] have described the roles of PKG in regulation
of aortic smooth muscle cell phenotype and in vascular disease.
PRKG1-transfected smooth muscle cells (SMC) express several-fold
higher levels of the contractile protein a-SMA and have a lower
proliferation rate relative to untransfected SMC [9]. We have
4678 Y. Zeng et al. / FEBS Letters 588 (2014) 4677–4685reported that both in short-term and chronic hypoxia PKG expres-
sion and activity are reduced in pulmonary vascular smooth mus-
cle cells [5,10]. However, it remains unclear how the functional and
transcriptional responses of PKG to hypoxia are mediated.
MicroRNA (miRNA), a class of evolutionarily conserved small
non-coding RNAs, have been identiﬁed as essential mediators in
a variety of cellular processes [11,12]. miR-20a belongs to the
miR-17–92 cluster, which is a conserved gene encoding seven miR-
NA and is located on chromosome 13q31 in the intron of
chr13orf25 [13]. This cluster is highly expressed in embryonic stem
cells [14] and plays a role in many malignancies, including B-cell
lymphomas [15], prostate carcinoma [16], gastric cancer [17],
and lung cancer [18]. There is a growing mass of evidence suggest-
ing that miR-20a is involved in cell proliferation and cell cycle reg-
ulation [19,20]. A recent study reported that miR-20a, via the
STAT3-miR-17/92 pathway, participates in the regulation of mor-
phogenetic protein receptor type 2 (BMPR2), which is a key deter-
minant of idiopathic familial pulmonary hypertension [21].
Subsequent work revealed that antagomiR directed against miR-
20a could restore functional BMPR2 signaling and prevent vascular
remodeling in hypoxia-induced pulmonary hypertension [22].
It is now widely accepted that miRNA modulate the expression
of their target genes in mammalian cells by forming imperfect
duplexes at the 30-UTR of mRNA [23,24]. More recently, it has been
demonstrated that miRNA can also regulate target mRNA by bind-
ing to its coding region [25,26] and several studies have depicted
the functional role of mammalian miRNA-mRNA interaction within
the coding regions [26–29]. Here we demonstrate that humanmiR-
20a can regulate PRKG1 expression post-transcriptionally through
its interaction with two conserved sites within the protein coding
sequence and play a pro-proliferation, pro-migration and anti-dif-
ferentiation role in PASMC.2. Materials and methods
2.1. Cell culture
HPASMC were maintained in SmGM-2 BulletKit Media (Lonza,
Basel, Switzerland) containing 5% FBS, growth factors, and antibiot-
ics. Hypoxia was achieved by using a special hypoxia incubator
with a gas mixture of 5% CO2 and balance nitrogen to keep oxygen
concentrations at 3%.
2.2. Human serum collection
Serum samples were collected from healthy participants and
patients with congenital heart disease-associated pulmonary arte-
rial hypertension (CHD-PAH) at the Sun Yat-Sen Cardiovascular
Hospital (Shenzhen, China). The blood samples were centrifuged
at 3000  g for 10 min at 4 C and stored at 80 C. The study
was approved by the ethics committee of Sun Yat-Sen Cardiovascu-
lar Hospital. All subjects who participated in the study provided
written informed consent.
2.3. Quantitative RT-PCR
Total RNA isolation was performed as previously described [30].
Change in expression of miR-20a was determined using the S-Poly
(T) method, as previously reported by us [31]. Sno202 and Sno44
were used as internal controls in mouse and human samples
respectively. PRKG1 mRNA levels were determined using SoFast-
EvaGreen Supermix (Bio-Rad, Hercules, CA) on a StepOnePlus
Real-Time PCR System (Applied Biosystems), normalized to the
internal control of ribosomal protein L19 (RPL19). Primers used
for reverse transcription and quantitative PCR are as follows:miR-20a, RT primer (5-GTG CAG GGT CCG AGG TCA GAG CCA
CCT GGG CAA TTT TTT TTT TTC TAC CT-3) and forward primer
(5-CCG GGT AAA GTG CTT ATA GT-3); sno44 RT primer (5-GTG
CAG GGT CCG AGG TCA GAG CCA CCT GGG CAA TTT TTT TTT TTA
GTC AG-3) and forward primer (5-TGG CCT GGA TGA TGA TAA
GCA-3); sno202 RT primer (5-GTG CAG GGT CCG AGG TCA GAG
CCA CCT GGG CAA TTT TTT TTT TTC ATC AG-3) and forward primer
(5-GTA CTT TTG AAC CCT TTT CCA T-3); PRKG1, sense (5-CAG GAA
AAG TGT TTG GGG AA-3) and antisense (5-TCG GTA TGC TTG ATG
AGT CCT-3); RPL19, sense (5-ATC ATC CGC AAG CCT GTG-3) and
antisense (5-TGA CCT TCT CTG GCA TTC G-3).
2.4. MiR-20a inhibition and overexpression
To knockdown endogenous miR-20a, anti-miR-20a inhibitors
and negative miRNA inhibitor control (Exiqon, Vedbaek, Denmark)
were used to transfect cells with Lipofectamine 2000 (Invitrogen).
Overexpression of miR-20a in HPASMC was generated using a len-
tiviral expression system (Clontech, Mountain View, CA). The pri-
miR-20a was ampliﬁed from human genomic DNA with the for-
ward primer (5-CAC CTC GAG CCT GCT ATT TCC TTC AA-3) and
reverse primer (5-GAG AAT TCA GTA ACA GGA CAG TTT G-3). Cells
stably overexpressing miR-20a or its negative control (without
miRNA sequence) were generated by puromycin (1.5 lg/ml)
selection.
2.5. Western immunoblot analysis
Total protein isolation and Western blot analysis were per-
formed as previously described [30]. Protein bands were then
probed with antibodies against MHC (ProteinTech, Chicago, IL),
PKG (Stressgen Biotechnologies, Victoria, Canada), p-VASP
(Cell Signaling Technology, Danvers, MA), b-tubulin, c-Myc, SM22
(Abcam, Cambridge, MA), calponin, a-SMA (Sigma Aldrich),
smoothelin (Santa Cruz Biotechnology, Santa Cruz, CA) or DsRed2
(Clontech). Band intensities were quantiﬁed using the NIH-ImageJ
software.
2.6. Luciferase reporter gene assay
Interaction of miR-20a with the PRKG1 promoter and 30-UTR
was analyzed by a dual reporter gene system, using a ﬁreﬂy lucif-
erase construct (pGL3-Luc) and a reference Renilla luciferase con-
struct (pRL-TK). PRKG1 promoter driven ﬁreﬂy luciferase vector
was kindly provided by Dr. Tom Lincoln (University of South Ala-
bama). PRKG1 30-UTR was cloned from genomic DNA with the for-
ward primer (5-CCG AAT TCT GTA TTT CTC TTA CCT GCT TC-3) and
reverse primer (5-CAC ACT AGT GGA CTC AGT TTA ATT TGT GG-3).
Fireﬂy and Renilla luciferase activity was measured independently
in cell extracts with a Lumat LB9508 luminometer (Berthold, Bad
Wildbad, Germany).
2.7. Immunocytochemistry
Cells grown on chamber slides were ﬁxed in 4% paraformalde-
hyde and permeabilized with 0.5% Triton X-100. Pretreated cells
were then incubated with a primary antibody against a-SMA
(Sigma Aldrich). Indirect immunoﬂuorescence was observed after
incubation with a secondary Alexa 488-conjugated anti-mouse
IgG (Jackson ImmunoResearch, West Grove, PA), with DAPI stained
for detecting nuclei.
2.8. Cell proliferation and migration assay
HPASMC proliferation and migration were determined by EdU
incorporation assay and wound-healing assay, respectively. EdU
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hou, China) according to the manufacturer’s instructions. Wound-
healing assay was performed as previously described [30]. Cell
migration was assessed at 12 h by measuring the decreased width
of the scratch. Data were presented as percentage of controls.
2.9. Statistical analysis
All data shown are mean values of at least three experiments,
each performed in triplicate, with standard errors (SE). The differ-
ences between groups were analyzed using the double-sided Stu-
dent’s t test or One-way ANOVA and a P value less than 0.05 was
considered signiﬁcant.
3. Results
3.1. Hypoxia induces miR-20a expression in lung, pulmonary artery
and serum
Mice were exposed to chronic hypoxia (10% O2) for 3 weeks to
induce pulmonary hypertension as previously described [32].
Expression of hypoxia-inducible factors (HIF) in lung tissue, endog-
enous marker for hypoxic effect identiﬁcation, was analyzed by
Western blotting. HIF-1a and HIF-2a expression increased with
duration of exposure to hypoxia (Fig. 1A). Quantitative real-time
PCR (qRT-PCR) assay revealed that miR-20a expression in the lungs
increased with duration of exposure to hypoxia. At 1 and 2-weeks
of hypoxia, miR-20a level was about 2-fold higher compared with
normoxic controls (Fig. 1B). The relative expression of miR-20a was
also assessed in isolated pulmonary arteries. Results showed that
miR-20a levels were increased over 3-fold after 2-weeks hypoxic
treatment compared with normoxic controls (Fig. 1C). It indicated
that miR-20a might be involved in the pathological changes of pul-
monary vascular in PAH. Serum miRNAs are currently regarded as
promising biomarkers to be applied in clinical diagnosis of PAH
[33]. As shown in Fig. 1D, upregulated serum miR-20a levels were
found in CHD-PAH patients compared with healthy subjects by
using qRT-PCR analysis. This result further highlighted miR-20a
as a potential circulating biomarker at least for CHD-PAH.Fig. 1. Induction of miR-20a by hypoxia in mouse lungs. (A) Western blot of lung HIF-1a
for 2 days (Hy-2d), 1 week (Hy-1w), 2 weeks (Hy-2w) and 3 weeks (Hy-3w). b-tubulin lev
lungs during the time course of exposure to hypoxia (n = 3 or 4 for each time point). Dat
shown as mean ± SE, ⁄P < 0.05 vs Nor-con (One-way ANOVA). (C) The relative expressio
shown as mean ± SE, ⁄⁄P < 0.01 (student’s t test). (D) miR-20a expression is measured in th
the healthy controls (n = 24). ⁄⁄P < 0.01 (student’s t test).3.2. MiR-20a is upregulated by hypoxia in HPASMC
To determine whether hypoxia-induced increase in expression
of miR-20a was also observed in HPASMC in vitro, we maintained
HPASMC either in normoxia (21% O2) or hypoxia (3% O2) for 48 h
and relative miRNA levels were measured by qRT-PCR. Western
blotting showed that HIF-1a and HIF-2a protein levels were
increased as anticipated (Fig. 2A). The expression level of miR-
20a was also upregulated about 2-fold at 48 h compared with nor-
moxia control (Fig. 2B). We then measured the mRNA and protein
levels of PRKG1. As shown in Fig. 2C and D, after 48 h of hypoxia,
the mRNA level of PRKG1 was reduced by about 19% and PKG pro-
tein level by 36%.
3.3. MiR-20a modulates the expression of PKG
To determine whether there is a direct relationship between
decreased PKG and increased miR-20a expression in hypoxia, we
investigated the effects of miR-20a overexpression and knockdown
on PKG expression in HPASMC. Cells were transfected with recom-
binant miRNA-expressing lentivirus or chemically synthesized
miRNA inhibitors. Transfection with miR-20a lentiviral particles
resulted in a 9-fold increase in miR-20a level relative to its scram-
ble control (miR-con) (Fig. 3A). On the other hand, inhibitors
against miR-20a (anti-20a) signiﬁcantly decreased miR-20a
expression by about 90% (Fig. 3B). Overexpression of miR-20a led
to a signiﬁcant decrease to about 50% in PKG protein levels
(Fig. 3C). Inhibition of miR-20a resulted in an increased expression
of PKG in HPASMC by 1.7-fold compared to negative control
(Fig. 3D). The results demonstrate that PKG is a likely downstream
target of miR-20a.
3.4. MiR-20a regulates PRKG1 gene by directly targeting its coding
region
To understand how miR-20a affects the expression of PKG, we
measured PRKG1 30-UTR activity when miR-20a was overexpres-
sed using a luciferase assay. Luciferase reporter gene assay was
performed in a 293T cell line. Enhanced expression of miR-20aand HIF-2a from control mice in normoxia (Nor-con), and mice exposed to hypoxia
els served as an internal control. (B) Quantitative RT-PCR assay of miR-20a in mouse
a were analyzed using the DDCt method by normalizing to endogenous sno202 and
n of miR-20a in pulmonary arteries of hypoxia-induced mice (2 weeks). Data are
e serum samples of CHD-PAH patients (n = 24) and is compared to the expression in
Fig. 2. Hypoxia causes increased miR-20a and decreased PKG expression in HPASMC. (A) Immunoblots of HIF-1a, HIF-2a and b-tubulin (as loading control) protein levels in
HPASMC incubated in either normoxia or hypoxia for 48 h. (B) The relative quantity of miR-20a was estimated by real-time PCR using sno44 levels for normalization. (C) The
relative mRNA levels of PRKG1 under normoxic or hypoxic conditions were normalized to RPL19 levels. Data are shown as mean ± SE relative to normoxia controls. (D)
Representative Western blot for hypoxia-induced decrease in PKG, with b-tubulin as a loading control. Protein bands were quantiﬁed and bar chart showing relative protein
levels was derived from triplicate samples. Data are shown as mean ± SE, ⁄P < 0.05 (student’s t test).
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PRKG1 promoter-driven luciferase assay was performed to identify
whether an indirect miRNA–mRNA interaction exists. As shown in
Fig. 4B, miR-20a did not have any effect on PRKG1 promoter activ-
ity. Next, we scanned through the entire PRKG1 gene transcript for
potential miR-20a binding sites. By using RNA22 software (IBM)
for analysis, we found two putative binding sites within the amino
acid coding sequence (CDS) of PRKG1. As shown in the schematic
diagram (Fig. 4C), the two predicted binding sites were located at
517–539 bp and 1058–1080 bp downstream of the transcriptional
initiation site. Furthermore, the two miR-20a target sequences,
especially the ‘seed region’ in the coding sequence of PRKG1, were
found to be highly conserved among six species (Fig. 4D).
To determine whether the observed decrease in PRKG1 expres-
sion by miR-20a overexpression was dependent on the two puta-
tive target sites, we ﬁrst constructed an cMyc-tagged wild type
PRKG1 overexpression vector and then performed non-sensemuta-
tion as indicated in Fig. 4D (named as Mut 1 or Mut 2) to disrupt the
recognition sites of miR-20a. The wild type and the two mutant
types (Mut 1 and Mut 2) of cMyc-PRKG1 vectors were then co-
transfected with miR-20a overexpression vector or control vector
into the cells. Another control vector of pDsRed2-C1 expressing
red ﬂuorescent protein was also included to normalize the transfec-
tion efﬁciency. Importantly, mutated sites did not affect the amino
acid of the fusion proteins, as veriﬁed by sequencing and immuno-
blot analysis (data not shown). Transient transfection and Western
blot analysis revealed that either Mut 1 or Mut 2 could partly abro-
gate the miR-20a-mediated suppression of cMyc-PKG protein.However, Mut 1 mutation seemed to reduce the effect of miR-20a
much more than Mut 2 based on the quantiﬁed protein bands
(Fig. 4E). These results strongly suggest that miR-20a downregu-
lates PRKG1 gene by interacting with the two binding sites within
its coding region.
3.5. MiR-20a effects the proliferation, migration and phenotype of
HPASMC
Adequate level of PKG expression is necessary to maintain vas-
cular smooth muscle in a well differentiated contractile phenotype.
Decreased PKG levels lead to increased cell proliferation and a
dedifferentiated phenotype [3,34,35]. Therefore we investigated
whether miR-20a was involved in regulating proliferation, differ-
entiation, as well as migration of HPASMC, which are critical for
vascular remodeling in the development of PAH. EdU incorporation
assay was carried out to assess the effect of miR-20a overexpres-
sion or knockdown on cell proliferation. As show in Fig. 5A and
B, the relative EdU positive cells in HPASMC that overexpressed
miR-20a was signiﬁcantly higher than in control cells (increased
by 24% vs miR-con). Conversely, miR-20a silencing reduced the
ratio of EdU positive cells by about 14% compared with anti-con.
In addition, results showed the reverse impact of PKG, relative to
miR-20a, on HPASMC proliferation (Fig. 5C and D).
Cell migration was assessed through a wound-healing assay. As
shown in Fig. 6A and B, the decrease in the width of the scratched
wound was larger in miR-20a transfected cells than that in control
cells after 12 h, and silence of miR-20a led to a decrease in wound
Fig. 3. MiR-20a represses the endogenous expression of PKG. (A) Quantitative real-time PCR showing increased expression of miR-20a in HPASMC transfected with
recombinant lentiviral particles expressing miR-20a (miR-20a), compared with its vector control (miR-con). (B) Relative miR-20a levels measured by quantitative PCR in cells
transfected with inhibitors against miR-20a (anti-20a) and its scramble control (anti-con). (C) Western blot showing miR-20a overexpression leading to decreased protein
level of PKG (upper panel). Fold change is normalized to b-tubulin and shown in bar chart at the bottom. (D) Western blot analysis showing miR-20a knockdown increases
PKG protein expression in HPASMC (upper panel). Relative quantiﬁcation of PKG protein is shown at the bottom. Data are shown as mean ± SE, ⁄⁄P < 0.01 (student’s t test).
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on cell migration was also analyzed. Results showed that enhanced
expression of PKG signiﬁcantly blocked the migration of HPASMC,
while PKG inhibition conversely accelerate this process (Fig. 6C and
D).
The expression of contractile phenotype markers were deter-
mined by Western blotting and immunocytochemistry. As shown
in Fig. 7A and B, increased expression of miR-20a signiﬁcantly
reduced the protein levels of calponin, SM22, a-SMA, smoothelin
and MHC. In contrast, miR-20a inhibition augmented smooth mus-
cle restricted proteins expression, especially calponin and a-SMA.
The level of PKG-mediated phosphorylation of vasodilator stimu-
lated phosphoprotein (p-VASP) implied miR-20a could also cause
repression on PKG activities. Meanwhile, PKG overexpression and
knockdown induced changes were also analyzed to conﬁrm its
functional relevance to miR-20a. Immunocytochemistry staining
for a-SMA revealed an expression pattern consistent with the ﬁnd-
ings from immunoblotting. MiR-20a overexpression revealed more
cells with a round, relaxed appearance and with a low ﬂuorescent
signal for a-SMA. Transfection with miR-20a inhibitors led to cells
with a high ﬂuorescent signal for a-SMA (Fig. 7C and D).
4. Discussion
In this study, we have described a new mechanism by which
PKG is post-transcriptionally downregulated in PASMC during
hypoxia. We have also characterized some of the biological effectsof miR-20a overexpression and knockdown in PASMC. Our data
demonstrate that hypoxia results in increased expression of miR-
20a, which leads to repression of PKG by the direct targeting of
the PKG gene coding region by miR-20a, resulting in increased pro-
liferation, migration and dedifferentiation.
MiRNA have long been shown to be important regulators of
gene expression at the post-transcriptional level. In plants, miRNA
primarily associate with protein coding regions by extensive base
pairing. In contrast, in animals, miRNA have been shown to inhibit
mRNA translation and to decrease the stability of mRNA by binding
to the sequences in the 30-UTR region [36]. However, there are a
few studies that have shown the functional role of mammalian
miRNA–mRNA interactions within the gene coding region
[26,28,29]. Here we have discovered another example of CDS-asso-
ciated miRNA regulation. We have shown that miR-20a signiﬁ-
cantly represses PKG protein expression in HPASMC. But we
found no interaction between miR-20a and the PKG gene promoter
or the 30-UTR region, although there is a poorly conserved miR-20a
binding site predicted in the PKG 30-UTR. By using computational
analysis and site mutation assays, we found two binding sites,
located in the coding region of PRKG1 gene, are responsible for
miR-20a recognition.
In mammals, miRNA typically bind to their targets with short
binding sequences making it difﬁcult to identify the binding sites
based on the sequence alone. So, prediction of miRNA-mRNA inter-
actions commonly relies on the evolutionary conservation of target
sites [37,38], a method that is more important for sequences
Fig. 4. MiR-20a targets the coding region of PRKG1. (A) Luciferase reporter assay to assess interaction between miR-20a and 30-UTR of PRKG1. (B) Luciferase assay of PRKG1
promoter activity following miR-20a overexpression in 293a cells. (C) Nucleotide sequence of the human PRKG1 transcript containing the potential binding sites for miR-20a.
There were two putative binding sites (site #1 and #2) predicted within the coding region and one binding site in the 30-UTR. (D) Sequence conservation of the two predicted
miR-20a binding sites within coding region of PRKG1 in six species. Red: paired bases; blue: A: C pair; underlined: mutant bases. (E) Western blot showing the effects of
mutation of the binding site on miR-20a recognition. Wild type or the two mutated PRKG1 constructs (pcDNA3-cMyc-PRKG1-wt, pcDNA3-cMyc-PRKG1-mut1 or pcDNA3-
cMyc-PRKG1-mut2) were co-transfected with miR-20a or its control overexpression vector along with pDsRed2-C1 vector. Exogenous cMyc-PKG protein levels were
immunoblotted with cMyc antibody and quantiﬁed using co-transfected DsRed2 level for normalization. The fold change in protein expression is shown in bar chart on the
right (mean ± SE). ⁄P < 0.05 and ⁄⁄P < 0.01 vs miR-con.
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ing sites within PRKG1 coding region are highly conserved
between variant transcripts, and among many species (chimpan-
zee, boar, cattle, rat, mouse, and rabbit), suggesting that these
sequences are precisely retained through evolution and have a
great potential for miRNA interaction.During the process of pulmonary vascular remodeling, the
dedifferentiation, migration and proliferation of PASMC are essen-
tial events happened in the early stage. Sheikh et al. have described
the program of distal arteriole muscularization in hypoxia-induced
PAH mice that encompasses SMC dedifferentiation, distal migra-
tion, proliferation, and then redifferentiation that ultimately lead
Fig. 5. MiR-20a promotes proliferation of HPASMC. (A) Representative images of EdU labeling showing proliferation of HPASMC either with miR-20a overexpression or
knockdown. DAPI staining was used to identify all the cells. (B) Bar chart showing the relative EdU positive cells after 24 h. (C) Representative images of EdU labeling showing
proliferation of HPASMC either with PKG overexpression or knockdown. Cells are transfected with recombinant lentiviral particles expressing PKG (PKG) or its vector control
(Control), or shRNA against PKG (sh-PKG) and its scramble control (sh-con). (D) Relative EdU positive cells are shown in bar chart (mean ± SE). Data are derived from three
independent experiments, with nine visual ﬁelds in triplicate samples. ⁄P < 0.05 and ⁄⁄P < 0.01 (student’s t test).
Fig. 6. MiR-20a promotes migration of HPASMC. (A) Representative images of wound-healing assay showing migration of HPASMC either with miR-20a overexpression or
knockdown. (B) Bar chart showing relative decreased wound width after 12 h. (C) Representative images of wound-healing assay showing migration of HPASMC either with
PKG overexpression or knockdown. (D) Bar chart of relative decreased wound width after 12 h. Data (mean ± SE) are derived from an average of three independent
experiments, with three visual ﬁelds in triplicate samples. ⁄P < 0.05 and ⁄⁄P < 0.01 (student’s t test).
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SMCs [39]. In our study, miR-20a levels in mouse lung showed
marked increase from 1 to 2 weeks of hypoxia, and then returned
to that of normoxia by 3 weeks. Therefore, the upregulation of
miR-20a was almost consistent with the acceleration of SMC pro-
liferation in response to hypoxia.
Brock et al. have reported their studies on the role of miR-20a in
hypoxia-induced pulmonary hypertension in mouse model [22].
Pulmonary arterioles stained for a-SMA showed that antagomiR-
20a injections signiﬁcantly reduces the vessel occlusion caused
by hypoxia and lessens the thickness of the vessel wall. They also
demonstrated that the proliferation of cultured PASMC was
repressed by antogomiR-20a transfection, which was accompanied
by decreased protein level of cell cycle inhibitor p21. They demon-
strated that the speciﬁc inhibition of miR-20a could restore func-
tional levels of BMPR2 both in vivo and in vitro. Dysregulation ofthe BMPR2 is a hallmark feature that has been described in several
forms of pulmonary hypertension [40–42]. It is also reported to be
a potent inducer of contractile phenotype and mediate induction of
contractile genes [43], and inhibition of PASMC growth and migra-
tion [44,45]. In this study, we showed that miR-20a could modu-
late the proliferation, migration and differentiation of human
PASMC via speciﬁc repression of PRKG1. Our current results
together with existing data in the literature provide strong evi-
dence to support the speciﬁc impact of miR-20a in the pathological
changes of PASMC in PAH.
PKG has long been shown to promote the maintenance of the
contractile phenotype of smooth muscle cell and to slow cell pro-
liferation. We have previously reported that in hypoxia PKG mRNA
and protein levels are decreased but we had not determined the
mechanism for this decrease. Hypoxia-induced increase in miR-
20a may partly account for this effect.
Fig. 7. MiR-20a downregulates the contractile protein expression in HPASMC. (A) Western blot of smooth muscle contractile proteins in miR-20a mimic or inhibitor
transfected HPASMC (left panel), and in HPASMC with PKG overexpression or knockdown (right panel). b-tubulin levels served as an internal control. (B) Protein bands were
quantiﬁed by normalization to b-tubulin and bar chart showing the relative protein levels in each manipulated group (vs. miR-con, anti-con, Control, and sh-con,
respectively). Data (mean ± SE) were derived from four independent experiments. ⁄P < 0.05 and ⁄⁄P < 0.01 (One-way ANOVA). (C) Immunocytochemistry showing effect of
miR-20a overexpression or knockdown on a-SMA expression in HPASMC, with miR-con and anti-con included as a reference. DAPI staining was used to identify cell nuclei.
Scale bar, 200 lm. (D) Relative a-SMA density is quantiﬁed and shown in bar chat. Data are derived from ﬁve visual ﬁelds in triplicate samples (mean ± SE). ⁄P < 0.05
(student’s t test).
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